What it is
PEG-MGF is Mechano Growth Factor (MGF) with polyethylene glycol (PEG) chains attached to it. MGF is a 24 amino acid peptide your body makes inside muscle after hard training. Its job is to switch on satellite cells, the muscle stem cells that repair and grow muscle fibres.
The problem with plain MGF is that it breaks down almost immediately. Its half-life, meaning the time it takes for half of it to disappear, is only about 5 to 7 minutes. That makes the standard version awkward to use, because it has to go straight into the trained muscle within minutes of finishing a session.
Adding PEG chains fixes that. The PEG forms a water-loving shield around the peptide that blocks the enzymes that would normally chew it up. That stretches the working life from 5 to 7 minutes to an estimated several hours, with some sources citing up to 48 to 72 hours. The PEG itself does not stick to anything in the body and leaves through urine.
One thing to be clear about upfront: there are zero published studies on PEG-MGF specifically. A PubMed search for "PEG-MGF" returns no results. Everything known is worked out from research on plain MGF plus the well-established pharmacology of PEGylation.
This is a research compound. It is not approved by the FDA for human use. It is banned by the World Anti-Doping Agency as a peptide hormone and growth factor, and also by the UFC, NFL, NCAA, NHL, MLB, NAIA and PGA.
PEG-MGF is the pegylated form of Mechano Growth Factor: the same 24 amino acid C-terminal E-domain peptide derived from the IGF-1Ec splice variant, with polyethylene glycol chains chemically attached to the peptide structure.
MGF is expressed locally in skeletal muscle following mechanical loading or damage and functions as the initial satellite cell activation signal. Native and synthetic MGF both carry a half-life of approximately 5 to 7 minutes, degrading in circulation almost immediately, which renders the unmodified peptide impractical outside direct intramuscular delivery at the trained site.
PEGylation creates a hydrophilic steric shield that physically obstructs proteolytic enzymes. The functional half-life is extended from approximately 5 to 7 minutes to an estimated several hours, with some sources citing up to 48 to 72 hours on the basis of general PEGylation pharmacokinetics. The PEG moiety itself is inert, does not bind other substances in the body, and is excreted renally.
The critical caveat is the evidence base. There are zero published studies specifically on PEG-MGF in any context, human or animal; a PubMed search for "PEG-MGF" returns no results. Every claim is inferred from two separately validated bodies of work — research on the non-pegylated MGF E-domain peptide and established PEGylation pharmacology — without direct validation of the combination.
Regulatory position: not FDA approved for human use, prohibited by WADA under peptide hormones and growth factors, and banned by the UFC, NFL, NCAA, NHL, MLB, NAIA and PGA.
How it works
When you train hard you create tiny tears in muscle tissue. Your body responds by releasing a short burst of MGF right at the damage. MGF wakes up satellite cells, the stem cells that sit dormant on the outside of muscle fibres. Once awake, those cells multiply and donate their nuclei to the damaged fibre. More nuclei means the fibre can build more protein and get bigger.
After that first burst, the body switches to making IGF-1Ea, the normal circulating form of IGF-1, which helps those activated cells mature and fuse into the fibre. PEG-MGF copies the first phase only.
Interestingly, the MGF piece appears to work through a signalling route called ERK1/2 rather than through the IGF-1 receptor. In plain terms, it uses a different switch than regular IGF-1 does, so the two are doing different jobs even though they come from the same gene.
The PEG chains do not change what the peptide does once it reaches a cell. They change how long it survives. Standard MGF has to go into the trained muscle within minutes. PEG-MGF gives you hours, and because it lasts longer in the blood it can reach muscle tissue from a fat-layer injection instead of needing to go straight into the muscle.
There is a trade-off worth knowing. Your body uses MGF as a brief pulse, not a steady signal. Keeping it around for hours is convenient but is not how the body normally does it. No study has compared pulse delivery against sustained delivery, so whether this matters is unknown.
One more piece of context: the ability to produce MGF after exercise drops with age, in line with falling growth hormone. Older people cannot raise MGF as effectively after training. When growth hormone was given alongside resistance exercise in older adults, MGF levels rose significantly, suggesting growth hormone is a main regulator of MGF. That age-related decline is part of the rationale for using it, particularly over 35.
PEG-MGF operates through the same mechanism as unmodified MGF; PEGylation alters duration of exposure, not receptor-level activity.
Mechanical loading and micro-damage trigger a rapid local pulse of MGF expression. The E-domain peptide activates quiescent satellite cells, which proliferate and donate myonuclei to damaged fibres, raising the fibre's capacity for protein synthesis. A second phase follows in which expression shifts to IGF-1Ea, the standard circulating isoform, driving differentiation and fusion of activated satellite cells into existing fibres. PEG-MGF replicates the first phase.
The E-domain peptide signals via ERK1/2 (extracellular signal-regulated kinase) independently of the IGF-1 receptor. This is a distinct route from full-length IGF-1 signalling, meaning PEG-MGF and IGF-1 perform different functions through different pathways despite arising from the same gene.
PEGylation changes pharmacokinetics alone. Unmodified MGF mimics the natural rapid pulse: fast onset, fast clearance, requiring intramuscular injection into the trained muscle within minutes of training. PEG-MGF persists for a considerably longer window, permitting a dosing window of hours and systemic distribution to muscle tissue rather than obligate local delivery. This is why subcutaneous administration is viable for PEG-MGF and effectively is not for standard MGF.
The unresolved trade-off: endogenous MGF functions as a brief pulse rather than a sustained signal. Prolonged exposure is pharmacologically convenient but is not the physiological pattern, and no study has compared biological outcomes of pulsatile versus sustained MGF delivery.
Age-related context from the non-pegylated literature: exercise-induced MGF expression declines with age in parallel with falling circulating growth hormone, and elderly subjects fail to upregulate MGF mRNA after exercise as effectively as younger subjects. Growth hormone administered alongside resistance exercise in older adults significantly enhanced MGF mRNA, implicating growth hormone as a principal regulator of MGF expression. This decline underpins much of the rationale for exogenous use in the over-35 demographic.
What it does
In practical terms, PEG-MGF is a recovery support tool. It signals satellite cells to activate so damaged muscle fibres can repair and grow. Because it lasts hours rather than minutes, one injection can support recovery across the body rather than only the spot where the needle went in.
Most people use it in one of two ways. Either injected into the muscle they just trained, to concentrate the effect on a lagging body part, or injected under the skin after training for general recovery support across whatever was trained that week.
What it does not do is act like a mass-building drug. Some vendor and clinic marketing claims 8 to 18 pounds of muscle gain in an 8 to 10 week cycle. No published research supports those numbers and they appear to be marketing claims. Treat it as recovery support layered on top of consistent training and adequate food, not as a shortcut.
The underlying MGF research also points to effects outside muscle. In animal work, the plain MGF E-domain peptide protected brain tissue during a lack of blood flow and promoted new nerve cell growth in ageing mice. Other animal work showed heart protection after a heart attack. None of this has been tested with PEG-MGF specifically.
Functionally, PEG-MGF is a satellite cell activator with an extended exposure window. The E-domain peptide initiates the proliferative phase of the muscle repair response; the PEG modification allows that signal to be delivered systemically and on a convenient schedule rather than as a site-specific post-training pulse.
In vitro research on the non-pegylated peptide showed MGF-24aa-E significantly increased the proliferative lifespan and delayed senescence of satellite cells isolated from neonatal and young adult human muscle, with less pronounced effects in cells from older donors. That finding is the core of the muscle rationale.
The systemic distribution afforded by PEGylation means a single injection can theoretically support recovery across multiple muscle groups. Despite this, intramuscular delivery into the trained muscle remains the preferred approach among practitioners targeting specific groups, on the basis of higher local concentration at the target tissue.
Beyond skeletal muscle, the non-pegylated E-domain literature reports neuroprotection equivalent to full-length IGF-1 but longer lasting in gerbil models of brain ischaemia, promotion of neurogenesis and preservation of olfactory function in the ageing mouse brain, and cardioprotection following myocardial infarction with 35% less compromised cardiac muscle than controls in a sheep model, mediated by prevention of mitochondrial membrane collapse and inhibition of apoptotic pathways. None of these effects has been tested with PEG-MGF.
Marketing claims of 8 to 18 pounds of muscle gain over an 8 to 10 week cycle have no published support and should be disregarded.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- Activates satellite cells, the muscle stem cells that repair damaged fibres and allow them to growAnimal or lab only
- Stays active for hours instead of minutes, so there is no need to rush from the gym to a syringeAnecdotal
- Can be injected under the skin as well as into muscle, which is more convenient and less painfulAnecdotal
- One injection can support recovery across more than one muscle group because it circulatesAnecdotal
- Can still be injected directly into a trained muscle to concentrate the effect on a lagging body partAnecdotal
- Users most often report reduced soreness and faster readiness to train the same muscle againAnecdotal
- Related research on plain MGF suggests brain and heart protective effects in animals, though not tested with PEG-MGFAnimal or lab only
- Satellite cell activation via ERK1/2 signalling, independent of the IGF-1 receptor, replicating the first phase of the natural repair responseAnimal or lab only
- Extended half-life allows sustained satellite cell stimulation compared with the brief pulse of unmodified MGFAnecdotal
- Research on non-pegylated MGF increased proliferative lifespan and delayed senescence of satellite cells from neonatal and young adult human muscle in cultureAnimal or lab only
- Systemic circulation permits recovery support across multiple muscle groups from a single injection, the main practical advantage over standard MGFAnecdotal
- Intramuscular delivery into the trained muscle remains available for localised concentration at a target siteAnecdotal
- Potential neuroprotection: the E-domain peptide matched full-length IGF-1 in gerbil brain ischaemia models with longer-lasting effects, and promoted neurogenesis in the ageing mouse brainAnimal or lab only
- Potential cardioprotection: 35% less compromised cardiac muscle than controls in a sheep myocardial infarction model, via prevention of mitochondrial membrane collapse and inhibition of apoptosisAnimal or lab only
- Lower hypoglycaemia risk than IGF-1 LR3, since the E-domain peptide appears to act outside the IGF-1 receptorAnecdotal
What to expect
There are no published clinical trials on PEG-MGF and no formal case reports. Everything below comes from anecdotal reports and from extrapolating the broader MGF research, so treat it accordingly.
Most people who report positive results describe subtle improvements in recovery over a 4 to 6 week cycle. Less soreness, being ready to train the same muscle group again a little sooner, and over time better development in the muscles that were specifically injected. Results are usually described as gradual rather than dramatic.
The strongest reports come from people injecting into a lagging body part straight after training that muscle. Improved quad and arm development are two commonly mentioned examples, generally over 4 to 8 week cycles. Users who expect overnight changes are generally disappointed.
Reports on PEG-MGF are generally more positive than reports on standard MGF, but that likely reflects how much easier it is to use correctly. The wider injection window and the subcutaneous option mean more people are actually administering it properly.
Side effects are usually mild and temporary. The most common are mild injection site reactions such as redness, swelling and minor pain, headaches and temporary water retention. Less common are low blood sugar symptoms, especially when carbohydrate intake is low, plus fatigue and joint discomfort. Eating a normal meal around injection time is a sensible precaution.
Set expectations honestly. This is a recovery support tool used alongside consistent training and good nutrition, not a mass-building shortcut.
No published clinical trials or formal case reports exist for PEG-MGF. All outcome data is anecdotal, drawn from external forums and peptide discussion platforms, and carries none of the weight of controlled research.
The consistent pattern is subtle improvement in recovery over a 4 to 6 week cycle: reduced DOMS, shortened turnaround before retraining a muscle group, and gradual improvement in the development of injected muscles. Users reporting the clearest effects are typically administering intramuscularly into lagging body parts immediately after training them, with quad and arm development the most commonly cited examples over 4 to 8 week cycles. Outcomes are described as subtle but noticeable when paired with consistent training and adequate nutrition.
Reports favour PEG-MGF over standard MGF, though this likely reflects compliance rather than potency. The wider dosing window, the subcutaneous option and a 2 to 3 times weekly schedule mean the protocol is far more likely to be executed correctly. Users who have run both generally report similar or slightly better results with significantly less hassle.
Adverse effects reported in practice are milder than with standard MGF, plausibly because subcutaneous delivery is less irritating and exposure is gradual rather than spiked. Common: mild injection site reactions, headaches, transient water retention. Less common: hypoglycaemic symptoms on low carbohydrate intake, fatigue, joint discomfort.
Two safety caveats specific to the pegylated form. Rare allergic reactions to PEG have been documented with other PEGylated compounds, and repeated exposure can theoretically drive anti-PEG antibody formation that reduces efficacy over time. Neither has been studied with PEG-MGF.
Vendor claims of 8 to 18 pounds of muscle over 8 to 10 weeks are unsupported marketing. This is recovery support, not a mass-building shortcut.
Reconstitution and dosing
No published dose-finding studies exist for PEG-MGF. The protocol below comes from clinical practice patterns, as users report them, not from controlled research.
The standard approach is 200 to 400 mcg per injection, 2 to 3 times per week on training days, post-workout. There is no rush here — within a few hours of training is fine. Cycles usually run 4 to 6 weeks, followed by an equal time off.
A typical week looks like this. Monday, train chest, inject 200 to 400 mcg into the chest or under the skin. Wednesday, train back, inject into the lats or under the skin. Friday, train legs, inject into the quads or under the skin.
How you use it depends on the goal. For targeted muscle growth, 200 to 400 mcg into the trained muscle, 2 to 3 times per week. For general recovery support, 200 mcg under the skin post-workout, 2 to 3 times per week. A more advanced approach is 400 mcg into the muscle on training days, alternating muscle groups.
On route, PEG-MGF gives a choice that standard MGF does not. Injecting into the trained muscle is still preferred by most practitioners targeting a specific body part, because it puts the highest concentration right at the target. Injecting under the skin is a valid option for general recovery and is more convenient and less painful. The longer-lasting form has time to circulate and reach muscle tissue even from a fat-layer site.
For mixing, a 2 mg vial with 1 mL of bacteriostatic water gives 200 mcg per 10 units on an insulin syringe.
A practical precaution: eat a normal meal around injection time, since some users report mild low blood sugar symptoms on low carbohydrate intake.
No dose-finding studies exist for PEG-MGF. Protocols derive from practice patterns, as users report them, rather than controlled research.
Standard protocol: 200 to 400 mcg per injection, 2 to 3 times per week on training days, administered post-workout with a window of a few hours rather than minutes. Preferred route is intramuscular into the trained muscle; subcutaneous is a valid alternative. Cycle length 4 to 6 weeks, with most protocols recommending an equal period off on the general principle of avoiding receptor desensitisation, as with IGF-1 LR3. No published data confirms whether cycling is necessary.
Application tiers. Targeted hypertrophy: 200 to 400 mcg IM into the trained muscle, 2 to 3 times weekly. General recovery support: 200 mcg subcutaneously post-workout, 2 to 3 times weekly. Advanced: 400 mcg IM on training days, alternating muscle groups.
Worked weekly example: Monday chest, 200 to 400 mcg IM into chest or subcutaneous; Wednesday back, same dose into lats or subcutaneous; Friday legs, same dose into quads or subcutaneous.
Route selection. Standard MGF is practically restricted to intramuscular delivery at the target site because of its 5 to 7 minute half-life. PEG-MGF's extended exposure removes that constraint, permitting systemic distribution to muscle from a subcutaneous depot. Intramuscular injection into the trained muscle remains preferred where the objective is a specific muscle group, on the grounds of maximal local concentration. Subcutaneous is more convenient and less painful and suits general recovery use.
Reconstitution: 2 mg vial with 1 mL bacteriostatic water yields 200 mcg per 10 units on an insulin syringe.
Eating a normal meal around injection time is a reasonable precaution given occasional reports of mild hypoglycaemic symptoms on low carbohydrate intake.
Standard, 2 mg vial
Mix with 1 mL (100 units) of bacteriostatic water.
2 mg/mL · 20 mcg per unit
Cycle: 4 to 6 weeks · Frequency: 2 to 3 times per week on training days, post-workout
| When | Dose | Draw | How often |
|---|---|---|---|
| Starting | 200 mcg | 10 units | per injection |
| Full | 400 mcg | 20 units | per injection |
2 mg in 1 mL is 2 mg/mL, or 20 mcg per unit. Draw 10 units (0.1 mL) for 200 mcg.
Who should avoid it
- Anyone with active cancer or a tumour. Growth factors could in theory speed up abnormal cell growth.
- Anyone with a past cancer diagnosis, unless an oncologist has cleared it first.
- Anyone with uncontrolled diabetes.
- Anyone with a known allergy to PEG or other pegylated products.
- Anyone who is pregnant or breastfeeding, as there is no safety data.
- Take care and speak to a doctor first if you have diabetes or blood sugar problems, heart disease, or liver or kidney trouble.
- Anyone using insulin or other blood sugar medicines, since this peptide sits in the IGF-1 family and may affect them.
- Anyone on steroid medicines such as dexamethasone, which may block the muscle-building effects.
- Tested athletes. PEG-MGF is banned by WADA and by the UFC, NFL, NCAA, NHL, MLB, NAIA and PGA.
- Active malignancy or existing tumours, on the theoretical basis that growth factor signalling could accelerate abnormal cell proliferation.
- History of malignancy without oncology clearance.
- Uncontrolled diabetes.
- Known allergy to PEG or pegylated compounds.
- Pregnancy or breastfeeding: no safety data exists.
- Caution in diabetes or impaired glucose regulation, given MGF's position in the IGF-1 family; also in cardiovascular disease and hepatic or renal impairment.
- Caution with insulin or other glucose-lowering agents due to possible IGF-1 family effects.
- Glucocorticoid therapy (for example dexamethasone) may inhibit MGF's growth-promoting effects.
- Any condition requiring medical supervision should be managed with a clinician involved.
- Drug-tested competition: PEG-MGF is a WADA prohibited substance under peptide hormones and growth factors, and is banned by the UFC, NFL, NCAA, NHL, MLB, NAIA and PGA. It is not FDA approved for human use and has no published human safety or efficacy data.
Side effects
- Mild reactions at the injection site such as redness, swelling or minor pain.
- Headaches.
- Temporary water retention.
- Low blood sugar symptoms, mostly when carbohydrate intake is low. Eating a normal meal around injection time is a sensible precaution.
- Tiredness.
- Joint discomfort.
- Most reports describe effects as mild and short-lived, and generally milder than with standard MGF because subcutaneous injection is an option.
- Rare allergic reactions to PEG have been recorded with other pegylated products, so an allergy to PEG rules this out.
- Common: mild injection site reactions (redness, swelling, minor pain), headaches, transient water retention.
- Less common: hypoglycaemia symptoms, particularly on low carbohydrate intake; fatigue; joint discomfort.
- No published safety studies exist on PEG-MGF. All safety information is inferred from the non-pegylated MGF E-domain literature and the established profile of pegylated therapeutic peptides.
- The E-domain peptide has been shown in some work to act independently of the IGF-1 receptor, which may make certain IGF-1 class risks such as strong insulin-like effects less relevant, though this has not been confirmed for PEG-MGF specifically.
- PEG itself is considered biologically inert and is widely used in pharmaceuticals, but rare allergic reactions to PEG are documented with other pegylated compounds.
- Repeated PEG exposure can theoretically drive anti-PEG antibody formation, which could reduce efficacy over time. This has been seen with other pegylated therapeutics but has not been studied with PEG-MGF.
- Side effects are reported as milder than with standard MGF, probably because subcutaneous injection is less irritating than intramuscular and because exposure is more gradual than a sharp spike.
What the evidence shows
There are no published studies on PEG-MGF itself. A search of PubMed for "PEG-MGF" returns nothing. Everything claimed about it is worked out from two separate things: research on the plain, non-pegylated MGF peptide, and the well-known drug technique of attaching PEG chains to make a peptide last longer.
On the MGF side, Kandalla and colleagues (2011) showed the MGF-24aa-E peptide made human muscle satellite cells live and divide for longer in the lab, with weaker effects in cells from older adults. Goldspink and colleagues (2003 to 2005) established that the body makes MGF as a quick burst after muscle damage and that older people make much less of it.
Not all the evidence points the same way. Fornaro and colleagues (2014) found MGF peptide at up to 500 ng/mL did not make muscle cells multiply, while full-length IGF-1 did. Janssen and colleagues (2016) found the short E-domain peptide sold as MGF did not switch on the IGF-1 receptor at any dose, although full-length MGF did. So the peptide may work through some other route that is not fully mapped out.
Attaching PEG to peptides reliably extends how long they survive in the blood, and that part is well proven across many medicines. What nobody has tested is whether a longer-lasting signal gives better, worse or the same result as the natural quick burst. PEG-MGF rests on two sound ideas put together without anyone checking the combination.
Zero published studies exist on PEG-MGF in any species. Every claim is extrapolated from the non-pegylated MGF E-domain literature plus general PEGylation pharmacology.
Kandalla and colleagues (2011), in Mechanisms of Ageing and Development, showed MGF-24aa-E significantly increased the proliferative lifespan and delayed senescence of satellite cells from neonatal and young adult human muscle cultures, with less pronounced effects in cells from older adults. This was in vitro work in human primary muscle cultures, not an in vivo trial. Goldspink and colleagues, across studies from 2003 to 2005, established that endogenous MGF is expressed as a rapid pulse after muscle damage, drives satellite cell activation, and is poorly upregulated in the elderly.
The counter-evidence is substantial. Fornaro and colleagues (2014), in American Journal of Physiology, reported that MGF peptide concentrations up to 500 ng/mL failed to increase myoblast or primary muscle stem cell proliferation, whereas full-length IGF-1 did produce a proliferative response. Janssen and colleagues (2016), in PLOS ONE, showed full-length MGF containing the complete IGF-1 domain could activate the IGF-1 receptor, while the synthetic E-domain peptides alone produced no IGF-1 receptor activation at any concentration. Any effect of the commercial peptide therefore likely runs through a separate, incompletely characterised route, with ERK1/2 signalling the proposed candidate.
Animal work on the non-pegylated E-domain peptide supports neuroprotection equivalent to full-length IGF-1 but longer lasting in gerbil brain ischaemia, neurogenesis in the ageing mouse brain, and cardioprotection with 35% less compromised cardiac muscle than controls in a sheep infarction model. None of this has been tested with the pegylated form.
PEGylation itself is well validated: PEG chains create a steric barrier against proteolysis, the PEG moiety is inert and renally excreted. What remains untested is whether sustained exposure reproduces, improves on, or blunts the outcomes of pulsatile MGF delivery.
User reports
From public forums
There are no clinical trials and no formal case reports on PEG-MGF. What follows comes from what users report, not from published data.
Most people who see results describe subtle improvements in recovery over a 4 to 6 week cycle: less soreness, being ready to train the same muscle again a little sooner, and slow improvement in muscles that were injected directly. Reports over 4 to 8 week cycles often mention better quad and arm development when those muscles were injected after training them. Results are usually called subtle but noticeable when training and food are already consistent. People expecting fast, dramatic change tend to be disappointed.
Users who put it into lagging body parts right after training them report the clearest results. That is the most commonly described use.
Almost everyone who has used both prefers PEG-MGF to standard MGF, mainly for convenience. There is no dash from the gym floor to a syringe, the subcutaneous option hurts less, and 2 to 3 injections a week is simpler than injecting after every session. Results are reported as similar or slightly better with far less hassle, though part of that may simply be that more people manage to use it correctly.
One warning on expectations. Some sellers and clinics claim 8 to 18 pounds of muscle in an 8 to 10 week cycle. No published research supports those numbers and they look like marketing. Treat this as a recovery support tool, not a shortcut to mass.
No published trials or formal case reports exist. Everything below is aggregated anecdote and carries less weight than published research.
The dominant report is improved recovery between sessions, reduced DOMS in injected muscles, and gradual development of lagging body parts across 4 to 8 week cycles. Intramuscular administration into the trained muscle post-session is the most frequently cited protocol among those reporting the clearest results, with quad and arm development mentioned specifically. Outcomes are consistently described as subtle but noticeable when training volume and nutrition are already adequate.
Users overwhelmingly prefer PEG-MGF to standard MGF on practical grounds. The extended half-life removes the requirement to inject within minutes of finishing training, the subcutaneous route is less painful than mandatory intramuscular dosing, and 2 to 3 injections per week is simpler than dosing after every session. Those who have run both report similar or slightly better results with significantly less hassle. The more favourable report profile may partly reflect higher rates of correct administration rather than superior pharmacology.
Side effect reports track standard MGF but are milder, largely attributed to the subcutaneous option and the smoother exposure curve. Mild injection site reactions, headaches, transient water retention and occasional hypoglycaemia symptoms on low carbohydrate intake dominate.
Vendor and clinic marketing claiming 8 to 18 pounds of muscle gain across an 8 to 10 week cycle has no published support and should be read as promotional. The realistic positioning is recovery support alongside a training stimulus.
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
No clash. Growth hormone peptides are usually taken on an empty stomach, before bed or first thing in the morning, while PEG-MGF is taken after training. Keep them on their own schedules. Growth hormone is a main controller of MGF production in muscle, so running a GH peptide may make the muscle more responsive to what PEG-MGF is doing.
No direct interaction concerns; different mechanisms and different timing requirements. GH secretagogues are dosed fasted, typically pre-sleep or on waking, while PEG-MGF is dosed post-workout. Growth hormone is a principal regulator of MGF expression in muscle, so a GHRH analogue may create a more responsive local environment for exogenous E-domain peptide signalling.
Works on a different system and at a different time of day. Ipamorelin is taken fasted, away from food; PEG-MGF goes in after training. No known interaction, just keep the timing separate.
No interaction concerns. Ipamorelin acts on the pituitary as a ghrelin receptor agonist, while PEG-MGF acts at the muscle on satellite cells via ERK1/2. Because growth hormone regulates MGF expression, secretagogue use may support the same endpoint from a different direction. Maintain separate fasted and post-workout schedules.
Another growth hormone peptide with no known clash. Take it fasted on its own schedule and keep PEG-MGF for after training.
No direct interaction concerns. Sermorelin drives endogenous GH release via GHRH receptors; PEG-MGF acts locally on satellite cells. Growth hormone being a principal regulator of MGF expression makes the pairing mechanistically coherent, though untested.
- HGH 191AA
These two can be used together. PEG-MGF does not act on the pituitary gland at all, so the feedback problem seen when stacking several growth hormone releasers does not apply. HGH works through the liver to lift IGF-1 across the body; PEG-MGF works locally at the muscle.
Compatible. PEG-MGF bypasses the pituitary entirely, acting as a growth factor directly on satellite cells, so the somatostatin feedback issue that limits stacking multiple GH secretagogues is not relevant. Exogenous HGH raises systemic IGF-1 through hepatic output while PEG-MGF signals locally; two distinct pathways, potentially complementary.
These do different jobs. PEG-MGF wakes up satellite cells, the first step in repair. IGF-1 LR3 pushes protein building and helps those cells mature, which is the second step. Some advanced users alternate them, but nobody has tested the combination. Note that IGF-1 LR3 must be cycled 4 to 6 weeks on and the same time off, and it carries a higher low blood sugar risk.
Mechanistically sequential rather than redundant. PEG-MGF drives satellite cell activation, the first phase of the natural repair response; IGF-1 LR3 drives protein synthesis and differentiation, aligning with the second phase. Some advanced users alternate them, typically across training and non-training days, but no published research has tested the combination. IGF-1 LR3 requires cycling at 4 to 6 weeks on with equal time off due to receptor desensitisation and carries greater insulin-like and hypoglycaemia risk, whereas PEG-MGF cycling rests on what users report rather than established pharmacology.
No known interaction. BPC-157 works on blood vessel growth and tissue repair signals; PEG-MGF works on satellite cells. They can be run at the same time and both can be injected under the skin.
No known interaction concerns. BPC-157 acts on angiogenesis and tissue repair signalling, PEG-MGF on satellite cell activation. Concurrent use is straightforward and both are subcutaneously compatible.
No known interaction. TB-500 works on cell movement and structure; PEG-MGF works on satellite cells. They can be run together, both under the skin.
No known interaction concerns. TB-500 acts via actin upregulation and cell migration, a distinct mechanism from satellite cell activation. Can be run concurrently, both subcutaneously.
No interaction concerns and no timing clash. If a GLP-1 is being used for weight loss, PEG-MGF may in theory help hold onto muscle by keeping satellite cells active, though this has not been studied.
No interaction concerns; entirely separate mechanisms and no timing conflict. During GLP-1 driven weight loss, satellite cell activation may theoretically support lean mass preservation, though this has not been studied.
No interaction concerns. Different mechanism, no timing clash. During a fat loss phase it may in theory help protect muscle, but that has not been tested.
No interaction concerns. Mechanistically unrelated and freely co-administered. Theoretical lean mass preservation via satellite cell activation during aggressive energy deficit remains untested.
The non-pegylated original. Same 24 amino acid peptide but it clears in about 5 to 7 minutes, so it has to go into the trained muscle within minutes of finishing. Most people choose one or the other rather than both.
The parent compound. Identical 24 amino acid C-terminal E-domain peptide with a half-life of approximately 5 to 7 minutes, which mandates intramuscular injection at the target site within minutes of training. PEG-MGF exists to remove that constraint; the two are alternatives rather than a stack, and the pulsatile versus sustained delivery question has never been compared in published work.
- Testosterone replacement therapy (TRT)
No interaction concerns. PEG-MGF can be run alongside TRT without problems.
No interaction concerns. Compatible with testosterone replacement therapy without dose or timing adjustment.
Common questions
Why use PEG-MGF instead of standard MGF?
Practicality. Adding PEG chains stretches how long the peptide lasts from minutes to hours, so there is no need to inject the moment a session ends or to hit the exact muscle that was trained. It can also go under the skin instead of only into muscle. The routine is simpler, less painful and easier to stick to. Users report similar or slightly better results with far less hassle.
PEGylation extends the functional half-life from approximately 5 to 7 minutes to an estimated several hours, removing the requirement for immediate post-training intramuscular injection into the worked muscle. Systemic persistence also makes subcutaneous administration viable. The protocol is simpler and adherence is better, and users who have run both report comparable or slightly superior outcomes with significantly less logistical burden.
Is there any published research on PEG-MGF?
No. There are zero published studies on PEG-MGF specifically, and a PubMed search returns no results. Everything known comes from research on the plain MGF peptide plus the well-established science of attaching PEG to peptides. That does not prove it fails. It means nobody has formally tested it.
None. A PubMed search for "PEG-MGF" returns no results, human or animal. All inference derives from the non-pegylated MGF E-domain literature combined with established PEGylation pharmacology. Absence of study is not evidence of inefficacy, but no direct validation of the combination exists.
How does PEG-MGF compare to IGF-1 LR3?
They do different jobs. PEG-MGF wakes up satellite cells, the first responders in muscle repair. IGF-1 LR3 pushes protein building and cell growth through the whole body. IGF-1 LR3 has stronger insulin-like effects and a higher risk of low blood sugar, and it must be cycled strictly. They are not swaps for each other, though some advanced protocols use both, usually alternating training and rest days.
Distinct roles. PEG-MGF drives satellite cell activation, the first responder phase of repair, apparently via ERK1/2 rather than the IGF-1 receptor. IGF-1 LR3 drives systemic protein synthesis and cell growth through IGF-1 receptor activation, carries stronger insulin-like effects and higher hypoglycaemia risk, and requires strict cycling due to receptor desensitisation. Not interchangeable; some advanced protocols run both, typically alternating training and non-training days.
Can PEG-MGF be injected under the skin?
Yes. Unlike standard MGF, it lasts long enough to travel through the blood and reach muscle from a spot under the skin. Injecting into the trained muscle is still preferred when targeting a specific body part, but under the skin is a fine choice for general recovery and it hurts less.
Yes. The extended half-life allows systemic distribution to muscle tissue from a subcutaneous depot, which standard MGF cannot achieve. Intramuscular injection into the trained muscle remains preferred where local concentration at a target group is the goal, since it delivers the highest local exposure, but subcutaneous administration is valid for general recovery support and is more convenient and less painful.
Does PEG-MGF need to be cycled?
Most protocols use 4 to 6 weeks on followed by the same length of time off. This comes from general practice and the idea of avoiding the body getting used to the signal, similar to how IGF-1 LR3 is handled. No published data confirms whether cycling is actually needed.
Standard practice is 4 to 6 week cycles with equal time off. This rests on user reports and the general principle of limiting receptor desensitisation, mirroring IGF-1 LR3 handling, rather than on data. No published work confirms whether cycling is necessary for PEG-MGF.
Will PEG-MGF cause low blood sugar?
The risk is lower than with IGF-1 LR3, because the MGF peptide appears to work through a different internal signal rather than the IGF-1 receptor. Even so, it sits in the IGF-1 family and some users report mild low blood sugar symptoms, especially when carbohydrate intake is low. Eating a normal meal around injection time is a sensible precaution.
Lower risk than IGF-1 LR3, since the MGF E-domain peptide appears to signal through ERK1/2 independently of the IGF-1 receptor. It nonetheless belongs to the IGF-1 family and mild hypoglycaemia symptoms are reported, particularly on low carbohydrate intake. Timing administration around a normal meal is a reasonable precaution, and caution applies in diabetes or with glucose-lowering medication.
Can women use PEG-MGF?
The satellite cell mechanism works the same regardless of sex, and the published MGF research used both male and female tissue samples. Women use the same doses in practice. Beyond the standard warnings listed, the published literature notes no sex-specific safety concerns.
Satellite cell activation is not sex-specific, and the published MGF research has been conducted in both male and female tissue samples. The same dosing protocols are used by women in practice. No sex-specific safety concerns appear in the published literature beyond the standard contraindications, with pregnancy and breastfeeding excluded for lack of data.
How long does PEG-MGF stay active?
Estimates vary. The usual figure quoted is several hours, with some sources claiming up to 48 to 72 hours based on how PEG normally behaves. No published study has measured this for PEG-MGF, so exact clearance time is unknown.
Estimates vary. Several hours is the commonly cited figure, with some sources claiming up to 48 to 72 hours based on general PEGylation pharmacokinetics, against approximately 5 to 7 minutes for the unmodified peptide. No pharmacokinetic study has been conducted on PEG-MGF to confirm half-life or clearance.
References
- Kandalla PK, Goldspink G, Butler-Browne G, Mouly V. Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mech Ageing Dev. 2011;132(4):154-162.
- Hill M, Goldspink G. Expression and splicing of the insulin-like growth factor gene in rodent muscle is associated with muscle satellite (stem) cell activation following local tissue damage. J Physiol. 2003;549(2):409-418.
- Goldspink G. Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology. 2005;20:232-238.
- Fornaro M, Hinken AC, Needle S, et al. Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells. Am J Physiol Endocrinol Metab. 2014;306(2):E150-E156.
- Matheny RW Jr, Nindl BC, Adamo ML. Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. Endocrinology. 2010;151(3):865-875.
- Dluzniewska J, Sarnowska A, Beresewicz M, et al. A strong neuroprotective effect of the autonomous C-terminal peptide of IGF-1 Ec (MGF) in brain ischemia. FASEB J. 2005;19(13):1896-1898.
- Zablocka B, Goldspink PH, Goldspink G, Gorecki DC. Mechano-Growth Factor: an important cog or a loose screw in the repair machinery? Front Endocrinol. 2012;3:131.
- Janssen JAMJL, Hofland LJ, Strasburger CJ, van den Dungen ESR, Thevis M. Potency of full-length MGF to induce maximal activation of the Akt/p70S6k signaling pathway. PLoS ONE. 2016;11(3).
- Carpenter V, Matthews K, Devlin G, et al. Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction. Heart Lung Circ. 2008;17(1):33-39.
- Mavrommatis E, Shioura KM, Los T, Goldspink PH. The E-domain region of mechano-growth factor inhibits cellular apoptosis and preserves cardiac function during myocardial infarction. Mol Cell Biochem. 2013;381(1-2):69-83.
- Tang JJ, Podratz JL, Lange M, et al. Mechano growth factor, a splice variant of IGF-1, promotes neurogenesis in the aging mouse brain. Mol Brain. 2017;10(1):23.
- Liu Y, Duan M, Zhang D, Xie J. The role of mechano growth factor in chondrocytes and cartilage defects: a concise review. Acta Biochim Biophys Sin (Shanghai). 2023;55(5):701-712.
- Sha Y, Chen L, Xu C, Zhang B, Hong H, Wang C. The Roles of IGF-1 and MGF on Nerve Regeneration under Hypoxia-Ischemia, Inflammation, Oxidative Stress, and Physical Trauma. Curr Protein Pept Sci. 2023;24(2):143-155.
This entry was written from additional reference material. Units are recomputed from the stated protocol.